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Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Magnesium has been reported to be 
effective in reducing the incidence or prophylaxis of AF. Magnesium is also an essential constituent of many enzyme 
systems and plays a physiological role in coagulation regulation. The aim of the present study was to examine the 
effects of magnesium, whether magnesium infusion might decrease the incidence of AF and induce hypocoagulable 
state in patients with AF, who were undergoing mitral valve annuloplasty.
Methods: This prospective laboratory study was performed using blood from patients with AF undergoing mitral 
valve annuloplasty. The radial artery was punctured with a 20 gauge catheter and used for monitoring continuous 
arterial pressure and blood sampling. After anesthesia induction, 4 g of magnesium was mixed with 100 ml normal 
saline and infused for 5 minutes. Magnesium, calcium, activated clotting time (ACT) and thromboelastographic 
parameters were checked before and 60 minutes after the magnesium infusion. The electrocardiography changes 
after magnesium infusion were also checked before commencing cardiopulmonary bypass.
Results: After magnesium infusion, the serum level of magnesium increased significantly but serum calcium did not 
change significantly. ACT did not change significantly before or after magnesium infusion. The thromboelastographic 
parameters showed no significant changes before or after magnesium infusion. None of the patients converted to 
sinus rhythm from AF after the magnesium infusion.
Conclusions: A magnesium infusion did not influence the course of AF and coagulation in patients during prebypass 
period with AF undergoing mitral valve annuloplasty. (Korean J Anesthesiol 2011; 61: 210-215)
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia. The association between AF and the risk of throm-
boembolic complications has long been recognized. The patho-
genesis of thromboembolic complications is multifactorial but 
may be attributed to a hypercoagulable state with hemostatic 
abnormalities and endothelial dysfunction in AF [1].
Several meta-analyses showed that intravenous magnesium 
is effective for decreasing the incidence or prophylaxis of AF 
[2-4]. Miller et al. [2] reported the effectiveness of magnesium 
on post-cardiac surgeries AF. Onalan et al. [3] reported effecti-
veness of magnesium on rapid AF in patients without surgeries. 
Ho et al. [4] that magnesium could be considered as a safe 
adjunct to digoxin in controlling the ventricular response 
in acute AF. Magnesium is also an essential constituent of 
many enzyme systems and plays a physiological role in the 
regulation of coagulation. Magnesium is thought to prevent 
the coagulation process but the effects of magnesium on 
coagulation, as evaluated by thromboelastography, are 
inconsistent. In situation of rapid intravenous fluid infusion, 
maintaining magnesium at the upper limit of normal value 
attenuates rapid hemodilution-induced coagulation change 
(clot formation rate prolongation) due to decreased magnesium 
level in healthy volunteers [5]. Magnesium significantly 
improves the hypocoagulable state toward normal in patients 
undergoing liver transplantation [6]. However, James and 
Neil [7] reported that magnesium has minimal effects on 
coagulation (small prolongation of r time and k time and r + k 
time at thromboelastography) and Ames et al. [8] reported that 
magnesium levels remained unchanged except for an increase 
of the α angle at thromboelastography in healthy volunteers. 
Additionally, there was one report that magnesium has no effect 
on the overall coagulation index in women with pre-eclampsia 
[9]. On the other hand, there were some investigations that 
magnesium interrupted platelet aggregation and adhesion so 
magnesium sulphate administration induced hypocoagulation 
state in vitro and in vivo studies [10,11].
We hypothesized that magnesium infusion might decrease 
the incidence of AF and induce platelet dysfunction and induce 
hypocoagulable state because it can affect platelet function and 
it is essential factor for coagulation. The aim of the present study 
was to determine the effects of magnesium to the course of AF 
and coagulation status in mitral valve disease patients with AF.
Materials and Methods
Study population
This prospective laboratory study was performed using blood 
from patients with AF undergoing mitral valve annuloplasty 
after obtaining institutional review board approval and 
informed consent from the patients. Patients were excluded if 
any of the following criteria were present: 1) urgent or emergent 
case, 2) reduced left ventricular function (ejection fraction < 
40%), 3) significant concomitant other valvular heart disease, 4) 
intra-cardiac shunt, 5) myocardial infarction or clinical angina 
for 14 days, 6) severe renal disease (serum creatinine > 2.0 mg/
dl) or 7) severe hepatic disease.
Anesthetic regimen
After establishing routine invasive (invasive radial arterial 
blood pressure) and non-invasive patient monitoring (pulse 
oximetry, electrocardiography, bispectral index and near 
infrared spectroscopy), anesthesia was induced and main-
tained using target-controlled infusion (Orchestra
ⓇBase 
Primea, Fresenius Vial, Brezins, France) of propofol (target 
concentration, 1.0-1.5 μg/ml) and remifentanil (target 
concentration, 10-20 ng/ml). Muscle relaxation was obtained 
with a bolus of rocuronium under the guidance of peripheral 
neuromuscular transmission monitoring. Tracheal intubation 
and central venous catheterization on an internal jugular vein 
were performed, and a transesophageal echocardiography 
probe (6T probe, GE Healthcare, Piscataway, NJ, USA) was 
inserted.
Definition of AF and disappearance of AF
AF was defined as an irregular narrow complex rhythm (in 
the absence of a bundle branch block) with absence of discrete 
P waves for at least 10 minutes in the general ward and upon 
arrival at the operating room [12]. The disappearance of AF was 
defined as at least 10 minutes of sustained sinus rhythm after 
magnesium infusion. Changes in electrocardiography after 
the magnesium infusion were checked before commencing 
cardiopulmonary bypass.
Blood sample and thromboelastography (ROTEM
Ⓡ, 
Pentapharm GmbH, München, Germany)
The radial artery was punctured with a 20 gauge catheter 
after a modified Allen’s test and an arterial tubing Luer-
lock connector was secured to the intra-arterial catheter. 
The pressure-tubing-transducer system was flushed with 
heparinized saline (heparin 5,000 U mixed in 1,000 ml normal 
saline). A blood sample was obtained after 10 ml of blood and 
heparinized saline were discarded from the radial artery. A 1 
ml arterial blood sample was obtained and arterial blood gas 
analysis for measuring magnesium and calcium was performed. 212 www.ekja.org
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A 2.5 ml arterial blood sample was obtained and activated 
clotting time (ACT) was measured by Hemochron Response
Ⓡ 
(ITC, Edison, NJ, USA) with celite activator. A 1 ml blood sample 
was obtained and collected in a tube containing sodium 
citrate (Vacuette
Ⓡ, Greiner Bio-One GmbH, Kremsmünster, 
Austria) thromboelastography. Before sample analysis, 
the thromboelstography instrument was calibrated and 
underwent daily quality control testing. Samples were collected 
and analysed simultaneously at 37
oC on a four-channel 
thromboelstography machine with HepTEM
Ⓡ (Pentapharm 
GmbH, München, Germany). All reagents were purchased from 
Pentapharm. Just after induction of anesthesia, magnesium, 
calcium, ACT and the thromboelstographic parameters were 
measured as baseline values.
Magnesium (4 g mixed in 100 ml normal saline) was infused 
for 5 minutes before anesthesia induction. After 60 minutes 
of magnesium infusion, magnesium, calcium, ACT and the 
thromboelstographic parameters were measured.
Thromboelstographic parameters
Clotting time (CT), clot formation time (CFT), α angle, 
maximum clot firmness (MCF) and maximum lysis (ML) were 
measured.
CT was the time until the initiation of clotting. CFT was the 
time from the initiation of clotting until the clot reached 20 mm, 
which represented the speed of clot formation. The α angle 
was the tangent of the curve made as 20 mm of firmness was 
reached and describes the kinetics of clot formation. MCF 
described the maximum amplitude of thromboelastogram and 
reflected clot strength. ML was the reduction in clot firmness 
in relation to MCF and represented maximum fibrinolysis 
detected during analysis (Fig. 1).
Statistics
The primary outcome variables were the thromboelsto-
graphic parameters. Reference values, from a pilot study of 10 
patients with AF undergoing mitral valve annuloplasty, were: 
CT, 172 ± 18 seconds; CFT, 81 ± 16 seconds; α angle, 75 ± 3
o; 
MCF, 60 ± 5 mm; ML, 18 ± 3%. A difference of 10% or more 
detected between baseline and after magnesium infusion was 
deemed clinically significant. For a power of 0.8 and an α value 
of 0.05, sample sizes of 11, 35, 4, 9 and 23 for CT, CFT, α angle, 
MCF and ML, respectively, were calculated to be appropriate.
The data were analysed using the Statistical Package for the 
Social Sciences (SPSS for Windows, ver. 12.0; SPSS Inc, Chicago, 
IL, USA). Changes in magnesium, calcium, ACT, CT, CFT, α 
angle, MCF and ML were compared between baseline and after 
magnesium infusion value using a paired t-test. All data are 
expressed as number of patients or the mean ± SD. A P < 0.05 
was deemed to be statistically significant.
Results
Thirty-nine patients with AF undergoing mitral valve annulo-
plasty were studied but four patients were excluded because of 
simultaneous tricuspid valve annuloplasty. Thus, 35 patients 
were included in the final analysis (Table 1).
After magnesium infusion, serum levels of magnesium 
increased significantly (0.46 ± 0.06 mmol/L vs. 0.89 ± 0.11 
mmol/L; P < 0.001) but the serum calcium level did not change 
significantly (1.15 ± 0.06 mmol/L vs. 1.14 ± 0.07 mmol/L; P = 
0.32) (Table 2). ACT did not change significantly before or after 
the magnesium infusion (137 ± 14 seconds vs. 138 ± 18 seconds; 
P = 0.53) (Table 2).
The thromboelstography parameters did not change 
significantly before or after the magnesium infusion: CT, 170 ± 
24 seconds vs. 172 ± 18 seconds (P = 0.70); CFT, 85 ± 33 seconds 
vs. 94 ± 50 seconds (P = 0.17); α angle, 74 ± 6
o vs. 73 ± 7
o (P = 0.21); 
MCF, 61 ± 6 mm vs. 59 ± 6 mm (P = 0.06); ML, 14 ± 5% vs. 14 ± 5% 
(P = 0.49) (Table 2).
None of the patients converted to sinus rhythm from AF after 
the magnesium infusion.
Discussion
Wang et al. [13] reported that the maintenance of low LA 
Fig. 1. Rotational thromboelastometry parameters. clotting time 
(CT), clot formation time (CFT), α angle, maximum clot firmness 
(MCF) and maximum lysis (ML).213 www.ekja.org
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wall tension and near normal size of LA was important factors 
to maintain normal sinus rhythm after mitral or tricuspid valve 
surgeries and Maze procedure. Wachtell et al. [14] also reported 
that LA size is strong predictor to the development of AF. 
Mitral valvular heart disease, increased left atrial pressure and 
volume overload, which lead to left atrial enlargement (LAE), is 
frequently associated with AF. The incidence of AF is known as 
30-40% in patients presenting mitral valve surgery [15]. Most 
studies about correlation between prophylactic magnesium 
and the incidence of AF have focused on coronary artery 
bypass grafting surgery (CABG) with cardiopulmonary bypass 
in cardiac surgeries [2,16]. A meta-analysis by Miller et al. [2] 
included, in the main, patients undergoing CABG (only CABG, 
1794 patients; CABG and valve surgery, 523 patients; only valve 
surgery, 70 patients) and did not fully clarify valve surgery, 
especially only mitral valve surgery. Therefore, the present study 
focused on mitral valve disease patients with AF before surgical 
correction.
The patients with AF, who were undergoing mitral valve 
annuloplasty, frequently underwent concomitant maze pro-
cedure and received postoperative amiodarone for AF. Preo-
perative magnesium infusion was more effective in prevention 
of postoperative AF, comparing with intra- or postoperative 
magnesium infusion in a meta-analysis by Miller et al. [2] 
and postoperative AF usually has a self limited course [17,18]. 
Therefore, pre- and intra-operative AF was focused in the 
present study.
Hypomagnesemia is a common disorder after cardiac sur-
geries and has a higher frequency in patients with AF [2,19]. 
Therefore, a magnesium infusion is highly effective prophylactic 
therapy for reducing the incidence of AF after cardiac surgery 
[2,16]. The mechanism of prevention of AF by magnesium 
infusion is not entirely known, but depletion of magnesium 
is associated with proarrhythmic and magnesium infusion 
significantly increases atrial refractoriness [20,21]. DiCarlo et al. 
[22] showed magnesium infusion increased refractoriness in 10 
patients with normal range of magnesium. We had performed 
pilot study before the present study and had got the results, 
showing 20% reduction of AF with changing from lower normal 
limit of magnesium to upper limit. Therefore, we thought that 
magnesium infusion could decrease the incidence of AF with 
normal range of magnesium in patients with AF undergoing 
mitral valve annuloplasty.
As mentioned above, AF in mitral valvular heart disease is 
a structural problem of left atrial size and an effort to decrease 
the occurrences of AF with prophylactic magnesium infusion 
might have the limitations without a reduction in left atrial size. 
Preoperative echocardiography also showed LAE (59.0 ± 11.8-
69.8 ± 20.7 mm) in the present study. As the results of structural 
changes of left atrium (LA) with AF, blood stasis on LA easily 
occurs and contributes to thrombus formation in LA in mitral 
valvular heart disease with AF. Black et al. [23] reported that 
a left atrial spontaneous echo contrast in AF, representing 
Table 1. Patient Characteristics
Gender (M/F)
Age
Smoking
Underlying disease
    Hypertension
    Diabetes mellitus
    Dyslipidaemia
    PCI history
    CVA history
Current medication
    Alpha blocker
    ARB
    ACEi
    Beta blocker
    Calcium channel blocker
    Aspirin
    Plavix
    Warfarin
    NTG
Echocardiography
    LVEF (%)
    LA size (mm)
Mitral valve disease
    Mitral valve stenosis
    Mitral valve regurgitation
    MrS
    MsR
SR after Mg infusion
14/21
60 ± 12
14
16
  3
  7
  2
  4
  4
  9
  5
10
  9
  9
  1
13
  1
64 ± 14
Minimum: 59.0 ± 11.8
Maximum: 69.8 ± 20.7
  8
13
  9
  5
  0
Data are expressed as numbers of patients or mean ± SD. PCI: 
percutaneous coronary intervention, CVA: cerebrovascular accident, 
ARB: angiotensin receptor blocker, ACEi: angiotensin converting 
enzyme inhibitor, NTG: nitroglycerin, LVEF: left ventricular ejection 
LA: left atrium, MrS: combined mitral stenosis and regurgitation but 
mainly stenosis, MsR: combined mitral stenosis and regurgitation 
but mainly regurgitation, SR after Mg infusion: sinus rhythm after 
magnesium infusion.
Table 2. Effects of Magnesium on Rotational Thromboelastometry 
with HepTEM
Ⓡ
Item (normal range) Baseline
After 60 minutes 
of Mg infusion
P value
Mg (0.45-0.60 mmol/L)
Ca (1.12-1.42 mmol/L,)
ACT (107-150 s)
CT (100-240 s)
CFT (30-110 s)
α angle (70-83
o)
MCF (50-75 mm)
ML (<15 %)
0.49 ± 0.06
1.15 ± 0.07
137 ± 14
170 ± 25
85 ± 33
74 ± 6
61 ± 2
14 ± 5
0.89 ± 0.11*
1.14 ± 0.07
138 ± 18
172 ± 18
94 ± 50
73 ± 7
59 ± 6
14 ± 5
<0.001
0.32
0.53
0.70
0.17
0.21
0.06
0.49
Data are expressed as mean ± SD. Mg: magnesium, Ca: calcium, 
ACT: activated clotting time, CT: clotting time, CFT: clot formation 
time, MCF: maximum clot firmness, ML: maximum lysis. *P < 0.05.214 www.ekja.org
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a hypercoagulable state, is related to left atrial dimensions, 
increased hematocrit and fibrinogen but is not related to 
platelet count and coagulation factor. This result indicates 
that AF coagulant properties are related to the interaction 
between the structural problem and hematologic change, 
and magnesium infusion might fail to change the coagulant 
properties.
The total dosage of magnesium has also been considered. 
Several studies investigating the effect of magnesium on the 
incidence of AF used from 2 to 25 g for from 30 minutes to 96 
hours [2-4], although Abraham et al. [24] reported that a single 
dose of 2.4 g magnesium sulphate is effective and the lower 
limit of normal serum magnesium before magnesium infusion 
changed into a higher limit after the magnesium infusion in the 
present study.
Magnesium is well known as a calcium (it was known as 
an essential ion for coagulation) antagonist and is believed to 
have anticoagulant effects. Magnesium induces a significant 
prolongation of bleeding time, mediated neither by changes in 
platelet count or aggregation pattern nor by changing the level 
or ratios of serum arachidonic acid metabolites in preeclampsia 
[25]. In contrast, magnesium is a crucial constituent of 
coagulation. It activates platelet aggregation in healthy 
volunteers [26] and all processes related to factor XI [27], and 
promotes coagulation. These different effects on coagulation 
suggest that magnesium may have different actions under 
various circumstances. The effect of magnesium on coagulation, 
evaluated by thromboelastography, also shows variable results 
according to coagulation state and pregnancy [5-9].
Lip et al. [28] reported that plasma levels of fibrinogen, fibrin 
D-dimer and vWF are increased in patients with chronic AF, 
comparing with sinus rhythm. These factors are predictive of 
cardiovascular events hence may be markers of prothrombin 
state in patients with AF. Li-Saw-Hee et al. [29] reported that 
there was no significant variation in indexes of thrombogensis, 
platelet activation and endothelial dysfunction between LA 
and peripheral artery or vein. Therefore, we thought that the 
thromboelastographic parameters at baseline in the present 
study would show hypercoagulabe state but it showed normal 
ranges. Because antiplatelet and anticoagulation medications 
made weakness of clot strength or induced prolongation of 
initiation of clotting in thromboelastography results [30], 
medications such as aspirin, plavix and warfarin in patients 
with AF might be associated with normal ranges for the 
thromboelastographic parameters. If these medications were 
not used to the patients in this study, the possibility seemed 
to tend to the hypercoagulation by thromboelastography 
parameters. However, according to the results of our study, the 
change of coagulation profile might not be significant. Further 
investigation for the effects of magnesium on coagulation of 
the patients without antiplatelet or anticoagulation medication 
would help to support the present study.
One limitation should be considered. The sample size of 
the present study was calculated from thromboelastographic 
parameters in the pilot study. If the sample sizes were calculated 
from reduction rate of AF, 108 for 10%, 42 for 5% and 30 for 3%, 
respectively were obtained. However, the sample sizes from 
meta-analysis by Ho et al. [4] were various (15, 18, 20, 34, 35 and 
so on) and the sample size of 35 patients in the present study 
was not thought to be insufficient.
In conclusion, magnesium infusion did not influence 
the course of AF or coagulation during prebypass period in 
mitral valve disease patients with AF undergoing mitral valve 
annuloplasty.
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